1. Scrip
  2. >>R&D

Shilpa Medicare’s Plan For Eylea Biosimilar Spells Ambition, But Path Not Easy

Humira Biosimilar Trial Recruiting

 
• By Vibha Ravi

Shilpa Medicare’s plan for trials of an Eylea biosimilar shows the company’s ambition to leapfrog to a biosimilars-led growth strategy, one that Indian majors like Cipla and Lupin pivoted to post a successful generics program. However, the path isn’t going to be easy and Biocon/Viatris, Samsung Biologics are ahead

Arrow being aimed at man flying with arrow in hand
Shilpa's Biosimilars Ambitions Could Face Obstacles • Source: Alamy

Shilpa Medicare Ltd, a fledgling compared to Cipla Limited, Lupin Limited and Zydus Lifesciences Limited, has started its biosimilars program much before in its life cycle than these companies, which embarked on biosimilars journeys after achieving a certain scale in their generics business.

The generics business in the world’s largest market – the US – continues to witness a sharp downturn in product...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Insmed’s PAH Data Indicate Potential To Surpass Established Therapies

 
• By Joseph Haas

Insmed’s inhaled treprostinil exceeded goals for reducing pulmonary vascular resistance and improving six-minute walk test distance in Phase IIb data.

NewAmsterdam’s CETP Inhibitor Improves Alzheimer’s Biomarkers

 
• By Mandy Jackson

Data from the BROADWAY trial testing LDL-C reduction in adults with ASCVD showed that obicetrapib improved Alzheimer’s disease biomarkers, including tau and amyloid. Analysts think the data could differentiate obicetrapib against competitors in the cholesterol market.

With ACIP Upheaval, Merck & Co. Among Those Left In A Lurch

 
• By Jessica Merrill and Bridget Silverman

Merck’s newly approved Enflonsia for RSV is one of the products that was expected to be recommended for use by the CDC advisory committee in June.

Genmab Looks To Keep Ahead Of Lilly In Folate ADCs

 
• By Andrew McConaghie

The firm has its ‘foot on the gas’ to accelerate development of its FRα-targeting antibody-drug conjugate, Rina-S, but rival Lilly is also moving rapidly into Phase III.

More from Scrip

Stock Watch: On Q1 Vaccine Sales And Measles Outbreaks

 
• By Andy Smith

A recent study suggested that measles could become endemic in the US due to low vaccination rates. However, first-quarter vaccine sales offered a more nuanced picture.

Merck & Co.’s RSV Antibody Approved In US In Time To Compete With Blockbuster Beyfortus

 
• By Mandy Jackson

The US FDA approved Merck’s Enflonsia (clesrovimab) to prevent RSV in newborns and infants on the same day Sanofi assured that it would ship Beyfortus in time for the 2025-2026 RSV season.

Metsera’s Amylin Analog Stars In Obesity Phase I

 
• By Joseph Haas

Intended as obesity monotherapy and for combination with the firm’s GLP-1 analog, MET-0233i showed best-in-class efficacy with placebo-like tolerability at low doses.